A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Study Identifier
150998-003
CT.gov Identifier
NCT02181517
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Macular Degeneration - Other
    • Study Drug
  • abicipar pegol
  • ranibizumab
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    50+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of wet age-related macular degeneration in at least 1 eye * Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye
    Exclusion Criteria:
    * Hypersensitivity, allergy, or anaphylactic reaction to iodine * Cataract or refractive surgery within the last 3 months * History of vitrectomy

    Protocol Summary

    This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.

    Study Locations

    Location
    Status
    Location
    Phoenix, Arizona, United States
    Status
    Not applicable